ClinicalTrials.gg
CompletedNCT03801343Updated Jan 11, 2019

Efficacy and Tolerance Evaluation of an Amino Acid Food Supplement

An interventional study of Nutrakos® in Skin Photoaging, sponsored by Derming SRL. Completed at 1 site in Italy. Open to female participants aged 35 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-11.

Sponsored by Derming SRL · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
35 Years to 70 Years
Sex
Female
01

Study summary

Skin moisturizing and elasticizing efficacy of an amino acid food supplement

Read the detailed description

Primary end point of this study was to evaluate the moisturizing and elasticizing activity of "Nutrakos®" Amino Acid Food Supplement, both photoexposed and not photoexposed on skin areas (forearm volar and dorsal surface) by non-invasive instrumental measurements; the product will be tested for 1 month by female subjects, aged 35-70 years with skin photoaging. An additional aim of this study was to evaluate the product tolerance both by investigator and volunteers.

02

Conditions studied

  • Skin Photoaging
03

In context

Lead sponsor

Derming SRL is the lead sponsor of 26 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • female sex,
  • 35-70 years,
  • skin phototype II and III according to Fitzpatrick's classification (see par. 8.2.1)
  • accepting to not change their habits regarding food, physical activity, body cosmetic and cleansing products;
  • accepting not to expose their body to strong UV irradiation (UV session, or sun bathes) during the entire duration of the study;
  • accepting to sign the form.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy;
  • lactation;
  • smokers;
  • alcohol or drug abusers;
  • skin phototype I, IV, V and VI according to Fitzpatrick's classification
  • subjects not in menopause who do not use adequate precautions in order to avoid pregnancies during the study;
  • subjects not in menopause who do not accept to perform the pregnancy test at T0 and at the end of the study (T1M);
  • (BMI) variation (± 1) during the study period;
  • change in the normal habits regarding food, physical activity, body cosmetic and cleansing use during the month preceding the test;
  • sensitivity to the test product or its ingredients (to be assessed by the investigator during the baseline visit);
  • subjects whose insufficient adhesion to the study protocol is foreseeable;
  • participation in a similar study currently or during the previous 6 months;
  • dermatitis;
  • presence of cutaneous disease on the tested area, as lesions, scars, malformations;
  • clinical and significant skin condition on the test area (e.g. active eczema, psoriasis, severe rosacea, scleroderma, local infections and severe acne);
  • diabetes;
  • endocrine disease;
  • hepatic disorder;
  • renal disorder;
  • cardiac disorder;
  • pulmonary disease;
  • cancer;
  • neurological or psychological disease;
  • inflammatory/ disease;
  • drug allergy;
  • anti-inflammatory drugs, anti-histaminic, topic and systemic , narcotic, antidepressant, immunosuppressive drugs (with the except of contraceptive or hormonal treatment starting more than 1 year before the study);
  • using of drugs able to influence the test results in the investigator opinion.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Nutrakos®

    12 female subjects aged 35-70, have taken during a meal, for the 1 month ,2 stick packs/die of the food supplement

    Dietary Supplement: Nutrakos®

Interventions

  • Dietary supplementNutrakos®

    "Nutrakos®" Amino Acid Food Supplement supplies a specific mixture of amino acids that has been proven to induce synthesis of collagen and elastin, the main proteins of derma structure in fibroblasts and keratocytes.

06

What researchers measure

Primary outcomes

  1. Change from baseline of superficial skin hydration

    Skin electrical capacitance value was measured mono-laterally on the right or left forearm (volar and dorsal surface) with Corneometer CM825 (Courage - Khazaka, Köln, Germany). The measure of the skin capacitance properties is an indirect expression of its hydration level.

    Time frame: Basal visit (T0), 2 weeks (T2W), 1 month (T1M)

  2. Change from baseline of deep skin hydration

    Tissue dielectric constant value of superficial and deep skin layers was measured mono-laterally on the right or left forearm (volar and dorsal surface) with MoistureMeterD (Delfin Technologies, Kuopio - Finland)

    Time frame: Basal visit (T0), 2 weeks (T2W), 1 month (T1M)

  3. Change from baseline of skin plastoelasticity

    Superficial and deep skin plastoelasticity were measured mono-laterally on the right or left forearm (volar and dorsal surface) with the instrument Dermal Torque Meter (Dia-Stron Ltd., UK).

    Time frame: Basal visit (T0), 2 weeks (T2W), 1 month (T1M)

Secondary outcomes

  1. Change from baseline of tolerance

    The food supplement tolerance was evaluated considering: any adverse event related to the study treatment, which occurred during the study; any judgement reported by the volunteers.

    Time frame: Basal visit (T0), 2 weeks (T2W), 1 month (T1M)

07

Study locations

1 site
  • DERMING
    Milano, MI 20159, Italy
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Dec 2018, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2019
First posted
Jan 11, 2019
StartActual
Nov 22, 2018
Primary completionActual
Dec 21, 2018
CompletionActual
Dec 21, 2018
Last update
Jan 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03801343
Lead sponsor
Derming SRL
Responsible party
Adele Sparavigna (Medical Doctor, Derming SRL) — Principal investigator
First posted
Jan 11, 2019
Start date
Nov 22, 2018
Primary completion
Dec 21, 2018
Completion
Dec 21, 2018
Last update
Jan 11, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion